{
    "clinical_study": {
        "@rank": "77306", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "MEDI8111"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for MEDI8111"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to investigate the safety, tolerability and pharmacodynamics of MEDI8111 after\n      single ascending doses in healthy male."
        }, 
        "brief_title": "To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Subjects", 
        "detailed_description": {
            "textblock": "A phase I, single-blind, randomised, placebo-controlled, single centre study to investigate\n      the safety, tolerability and pharmacodynamics of intravenous MEDI8111 after single ascending\n      doses in healthy male subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed and dated, written informed consent prior to any study specific\n             procedures, Healthy male subjects aged 18-40 years with suitable veins for\n             cannulation or repeated venepuncture, Have a body mass index (BMI) between 18 and 30\n             kg/m2 inclusive and weight at least 50 kg an no more than 100 kg inclusive, Male\n             subjects should be willing to avoid fathering a child by either true abstinence or\n             the use of two effective means of contraception from the day of dosing until 3 months\n             after dosing with the IP. They should also be willing to use barrier methods from the\n             day of dosing until 3 months after dosing.\n\n        Exclusion Criteria:\n\n          -  Prothrombotic mutation such as factor V Leiden, or deficiencies of protein C, protein\n             S, prothrombin, antithrombin or APC, Antibodies to coagulation FII, History or family\n             history of venous or arterial thromboembolic event, and/or myocardial infarction\n             before age of 50 years, ETP level at baseline >2000nM/min, FII level (by clot) at\n             screening and/or at baseline outside 50-250% of the normal range"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958645", 
            "org_study_id": "D5050C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "description": "MEDI8111 lyophilisate for solution for infusion", 
                "intervention_name": "MEDI8111", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B", 
                "description": "Placebo for MEDI8111 saline solution for infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Phase 1, healthy male subjects, safety and tolerability, pharmacodynamic, pharmacokinetic", 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Single-blind, Randomised, Placebo-controlled, Single Centre Study to Investigate the Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses in Healthy Male Subjects", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Quintiles London (QLON) London England Quiniles London (QLON) London England", 
            "phone": "+44 0 800 634 11 32"
        }, 
        "overall_official": [
            {
                "affiliation": "AstraZeneca M\u00f6lndal, Sweden", 
                "last_name": "Karin Wahlander, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "AstraZeneca M\u00f6lndal, Sweden", 
                "last_name": "Anders Berggren, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Quintiles London, United Kingdom", 
                "last_name": "Timothy Mant, Prof", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare product Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Description of the safety profile in terms of adverse events (AE),vital signs, ECG, telemetry, lab variables, immunogenicity and physical examination", 
            "safety_issue": "Yes", 
            "time_frame": "From screening and up to the lab follow-up visit (Day 29)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958645"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Description of the pharmacodynamic (PD) profile in terms of endogenous thrombin potential (ETP)", 
                "safety_issue": "No", 
                "time_frame": "At screening, Days 1-5 and clinical follow-up (Day 15)"
            }, 
            {
                "measure": "Description of the PD profile in terms of prothrombin time (PT) , activated partial thrombin time (aPTT), fibrinogen, prothrombin fragment 1 + 2, d-dimer, thrombin anti-thrombin complex (TAT)", 
                "safety_issue": "No", 
                "time_frame": "At screening, Day -1, Days 1-5, 7, clinical follow-up (Day 15) and lab follow-up (Days 22 and 29)"
            }, 
            {
                "measure": "Description of the pharmacokinetic (PK) profile in terms of Factor II plasma concentrations (measured by 3 assay methods:Factor (F) II antigen assay, prothrombinase assay and FII clot assay)", 
                "safety_issue": "No", 
                "time_frame": "Screening, Day -1, -30 min before inf, 0 h, 20 min, 40 min, 59 min, 62-65 min, 1.25 h, 1.5 h, 2h, 3h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 144h after start of inf, clinical follow up (Day 15) and lab follow up (Days 22 and 29)"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}